MDEChem, Inc. (MDKM)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MDEChem, Inc. (MDKM) with AI Score 46/100 (Weak). MDEChem, Inc. is a biotechnology company that provides pharmaceutical and chemical products. Its offerings include MaxHeal skin restoration gel and SANDKLENE 950 for oil recovery. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 18, 2026MDEChem, Inc. (MDKM) Healthcare & Pipeline Overview
MDEChem, Inc., founded in 1996, develops and markets pharmaceutical and chemical products, including MaxHeal skin restoration gel and SANDKLENE 950. Operating within the biotechnology sector, the company addresses niche markets in skincare and oil recovery with its specialized product offerings, competing with larger, more diversified healthcare and chemical companies.
Investment Thesis
Investing in MDEChem, Inc. (MDKM) presents a high-risk, high-reward scenario. The company's market capitalization is $0.00B, reflecting its small size and limited market presence. The potential upside lies in the successful commercialization of MaxHeal and SANDKLENE 950. Growth catalysts include expanding distribution channels for MaxHeal and securing contracts within the oil sands industry for SANDKLENE 950. However, the company's beta of -28.87 indicates extreme volatility. Key risks include limited financial resources, reliance on a small product portfolio, and competition from larger companies with greater R&D and marketing capabilities. Investors should carefully consider the company's OTC market listing and associated risks before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- MDEChem, Inc. offers MaxHeal skin restoration gel, a non-steroidal and anti-inflammatory compound.
- The company provides SANDKLENE 950, a non-toxic chemical composition used in oil recovery from tar/oil sands.
- MDEChem, Inc. was founded in 1996 and is based in Floresville, Texas.
- The company operates with a single employee, indicating a highly lean operational structure.
- MDEChem's market capitalization is $0.00B, reflecting its micro-cap status.
Competitors & Peers
Strengths
- Specialized product offerings in niche markets.
- Non-toxic chemical composition of SANDKLENE 950.
- Potential for high margins on specialized products.
- Lean operational structure with low overhead.
Weaknesses
- Limited financial resources and market presence.
- Reliance on a small product portfolio.
- Dependence on key personnel.
- OTC market listing increases volatility and risk.
Catalysts
- Upcoming: Potential partnerships with larger pharmaceutical or chemical companies by Q4 2026 could expand market reach.
- Upcoming: Positive results from pilot projects for SANDKLENE 950 in oil sands recovery by Q3 2026 may lead to new contracts.
- Ongoing: Increasing consumer demand for natural and non-steroidal skin treatments drives sales of MaxHeal.
- Ongoing: Growing awareness of environmental concerns in the oil sands industry may increase demand for SANDKLENE 950.
- Upcoming: Regulatory approvals for new applications of MaxHeal by Q2 2027 could expand its market potential.
Risks
- Potential: Competition from larger companies with greater resources could erode market share.
- Potential: Regulatory hurdles and compliance costs could increase expenses.
- Potential: Fluctuations in energy prices could affect demand for SANDKLENE 950.
- Ongoing: Limited financial resources may constrain growth opportunities.
- Ongoing: OTC market listing increases volatility and risk.
Growth Opportunities
- Expanding the distribution network for MaxHeal skin restoration gel represents a significant growth opportunity. The global market for topical skin treatments is estimated at billions of dollars, with a growing demand for natural and non-steroidal alternatives. MDEChem could partner with major retailers and online platforms to increase product availability and reach a wider customer base. A successful expansion could significantly boost revenue and market share by 2027.
- Securing contracts with oil sands operators for SANDKLENE 950 offers another avenue for growth. The oil sands industry is under increasing pressure to adopt environmentally friendly extraction methods. SANDKLENE 950's non-toxic composition could appeal to operators seeking to reduce their environmental impact. Successful pilot projects and regulatory approvals could lead to long-term contracts and substantial revenue growth by 2028.
- Developing new formulations and applications for MaxHeal skin restoration gel could drive product innovation and differentiation. The company could explore new therapeutic areas, such as wound healing or anti-aging, to expand the product's market potential. Clinical trials and regulatory approvals would be necessary to support these new applications, with potential market entry by 2029.
- Exploring strategic partnerships with larger pharmaceutical or chemical companies could provide access to additional resources and expertise. A partnership could accelerate product development, expand distribution channels, and enhance marketing efforts. A successful partnership could significantly enhance MDEChem's competitive position and growth prospects by 2027.
- Expanding into international markets represents a long-term growth opportunity. The global market for skin care products and oil recovery solutions is vast, with significant potential in emerging economies. MDEChem could target specific regions with tailored marketing strategies and distribution networks. International expansion would require significant investment and careful planning, with potential market entry by 2030.
Opportunities
- Expanding distribution channels for MaxHeal.
- Securing contracts with oil sands operators for SANDKLENE 950.
- Developing new formulations and applications for existing products.
- Exploring strategic partnerships with larger companies.
Threats
- Competition from larger companies with greater resources.
- Regulatory hurdles and compliance costs.
- Fluctuations in energy prices affecting demand for SANDKLENE 950.
- Product liability claims and recalls.
Competitive Advantages
- Proprietary formulations for MaxHeal and SANDKLENE 950.
- Niche market focus in skin restoration and oil recovery.
- Potential for brand recognition and customer loyalty.
- Non-toxic chemical composition of SANDKLENE 950 offers a competitive advantage in the oil sands market.
About MDKM
MDEChem, Inc., established in 1996 and headquartered in Floresville, Texas, operates within the healthcare sector, specifically in the biotechnology industry. The company focuses on developing and marketing specialized pharmaceutical and chemical products. Its primary product, MaxHeal skin restoration gel, is designed to provide relief from minor skin irritations, cuts, burns, and insect bites. This non-steroidal, anti-inflammatory gel targets a broad consumer base seeking over-the-counter solutions for common skin ailments. Additionally, MDEChem offers SANDKLENE 950, a non-toxic chemical composition used in the recovery of oil from tar/oil sands. This product caters to the energy sector, providing a potentially environmentally friendly solution for oil extraction. MDEChem's small size and focused product line differentiate it from larger, more diversified pharmaceutical and chemical companies. The company's success hinges on the efficacy and market acceptance of its niche products, as well as its ability to navigate the regulatory landscape and compete with established players in both the healthcare and energy sectors.
What They Do
- Develops and markets MaxHeal skin restoration gel for minor skin irritations.
- Offers SANDKLENE 950, a non-toxic chemical composition for oil recovery from tar/oil sands.
- Provides solutions for relief from minor cuts, scrapes, minor burns, sunburn, and abrasions.
- Soothes itchy bites from chiggers, mosquitoes, sand fleas, black flies, and other biting insects.
- Focuses on niche markets within the healthcare and energy sectors.
- Operates with a small team and a lean operational structure.
Business Model
- Generates revenue from the sale of MaxHeal skin restoration gel through retail channels and online platforms.
- Generates revenue from the sale of SANDKLENE 950 to oil sands operators.
- Focuses on developing and marketing specialized products for niche markets.
- Relies on direct sales and distribution channels to reach customers.
Industry Context
MDEChem, Inc. operates in the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for skin restoration products is driven by consumer demand for effective over-the-counter treatments for minor skin irritations. The oil sands recovery market is influenced by energy prices and environmental regulations. MDEChem's success depends on its ability to differentiate its products and compete with larger companies with greater resources. The company's small size and focused product line present both opportunities and challenges in this dynamic environment.
Key Customers
- Consumers seeking over-the-counter solutions for minor skin irritations.
- Oil sands operators looking for environmentally friendly oil recovery solutions.
- Retailers and online platforms that sell healthcare and chemical products.
- Individuals seeking relief from insect bites and minor skin injuries.
Financials
Chart & Info
MDEChem, Inc. (MDKM) stock price: Price data unavailable
Latest News
No recent news available for MDKM.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MDKM.
Price Targets
Wall Street price target analysis for MDKM.
MoonshotScore
What does this score mean?
The MoonshotScore rates MDKM's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Paul W. Sack
Managing
Paul W. Sack serves as the managing executive of MDEChem, Inc. His background includes experience in the pharmaceutical and chemical industries. He has been involved in the development and marketing of specialized products for niche markets. His expertise lies in identifying market opportunities and developing innovative solutions to meet customer needs. He is responsible for overseeing all aspects of the company's operations, from product development to sales and marketing.
Track Record: Under Paul W. Sack's leadership, MDEChem, Inc. has developed and launched MaxHeal skin restoration gel and SANDKLENE 950. He has focused on building a lean operational structure and developing strategic partnerships to expand the company's reach. Key milestones include securing regulatory approvals for the company's products and establishing distribution channels in key markets. He manages 1 employee.
MDKM OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MDEChem, Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the lack of transparency and potential for fraud.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial resources and market presence.
- Lack of regulatory oversight and transparency.
- Potential for fraud and manipulation.
- Low trading volume and liquidity.
- Dependence on key personnel.
- Verify the company's financial statements and disclosures.
- Investigate the background and experience of the company's management team.
- Assess the company's competitive position and market opportunities.
- Evaluate the company's regulatory compliance and legal risks.
- Determine the company's ownership structure and control.
- Understand the company's business model and revenue streams.
- Assess the company's liquidity and trading volume.
- The company has been in operation since 1996.
- The company has developed and launched two products: MaxHeal and SANDKLENE 950.
- The company has a website and contact information.
- The company is based in Floresville, Texas.
MDEChem, Inc. Stock: Key Questions Answered
What does MDEChem, Inc. do?
MDEChem, Inc. is a biotechnology company that develops and markets specialized pharmaceutical and chemical products. Its primary product, MaxHeal skin restoration gel, is a non-steroidal, anti-inflammatory compound designed to provide relief from minor skin irritations, cuts, burns, and insect bites. The company also offers SANDKLENE 950, a non-toxic chemical composition used in the recovery of oil from tar/oil sands. MDEChem focuses on niche markets within the healthcare and energy sectors, targeting consumers and businesses seeking specialized solutions.
What do analysts say about MDKM stock?
As of March 18, 2026, there is no available analyst coverage for MDKM stock due to its OTC listing and small market capitalization. Key valuation metrics are not readily available. Growth considerations include the successful commercialization of MaxHeal and SANDKLENE 950, as well as the company's ability to secure contracts and expand its distribution network. Investors should conduct their own due diligence and carefully consider the risks associated with investing in MDKM.
What are the main risks for MDKM?
The main risks for MDKM include its limited financial resources, reliance on a small product portfolio, and competition from larger companies with greater R&D and marketing capabilities. The company's OTC market listing increases volatility and risk. Fluctuations in energy prices could affect demand for SANDKLENE 950. Regulatory hurdles and compliance costs could also impact profitability. Investors should carefully consider these risks before investing in MDKM.
What are the key factors to evaluate for MDKM?
MDEChem, Inc. (MDKM) currently holds an AI score of 46/100, indicating low score. Key strength: Specialized product offerings in niche markets.. Primary risk to monitor: Potential: Competition from larger companies with greater resources could erode market share.. This is not financial advice.
How frequently does MDKM data refresh on this page?
MDKM prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven MDKM's recent stock price performance?
Recent price movement in MDEChem, Inc. (MDKM) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Specialized product offerings in niche markets.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider MDKM overvalued or undervalued right now?
Determining whether MDEChem, Inc. (MDKM) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying MDKM?
Before investing in MDEChem, Inc. (MDKM), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available due to OTC listing and lack of analyst coverage.
- Financial data is based on available information and may not be comprehensive.